Review of the recent advances of pyrazole derivatives as selective COX-2 inhibitors for treating inflammation

• Published in: Molecular diversity
• Main Authors: Ghoneim, Mohammed M, Abdelgawad, Mohamed A, Elkanzi, Nadia A A, Bakr, Rania B
• Format: Journal Article
• Language: English
• Published: Netherlands 16-07-2024
• Subjects: SAR studies; COX-2 inhibitors; Docking study; Anti-inflammatory; Pyrazole
• ISSN: 1381-1991; 1573-501X; 1573-501X
• DOI: 10.1007/s11030-024-10906-9

Pyrazole heterocycle is regarded as an extremely significant agent for the therapy of inflammation. Celecoxib, lonazolac, deracoxib, and phenylbutazone are examples of commercially approved pyrazole drugs with COX-2 inhibitory potential for curing inflammation. There have been recently many reviews for the biological significance of pyrazole derivatives. This review talks about pyrazole derivatives with anti-inflammatory activity and also sheds the light on the recent updates on pyrazole research with an emphasis on some synthetic pathways utilized to construct this privileged scaffold and structure activity relationship that accounts for the anti-inflammatory activity in an attempt to pave the opportunity for medicinal chemists to develop novel anti-inflammatory agents with better COX-2 selectivity.